Compare DexCom, Inc. (DXCM) vs iShares Gold Trust (IAU) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

IAU shares are trading at $74.92, down 1.77% amid broader gold market weakness. The technical picture shows bearish momentum with selling pressure across moving averages, while oscillators remain neutral. Recent economic data including stronger retail sales and manufacturing activity have pressured gold prices, offsetting earlier inflation relief. The stock faces resistance at $77 with support at $76.

The outlook remains cautious as Federal Reserve policy uncertainty and Treasury yield movements continue to drive gold price volatility. While central bank accumulation provides long-term support, near-term headwinds from economic data and dollar strength suggest continued pressure. Investors should monitor Fed communications and inflation trends for directional catalysts.